Content and data provided by various third parties and Fidelity − Terms of Use

Stock Details

RELATED RESOURCES

News & Events:NSPR

INSPIREMD INC

2.67Up 0.03 (1.1364 %)as of 9:33:46am ET 01/26/2022

Quotes delayed at least 15 min. Log in for real time quote.

Log in for more news Show all article details.Expand all| Hide all article details.Collapse all
  1. Show article details.

    InspireMD Announces Live Case Broadcast at ISET 2022 Conference Following the Supplement Approval by the FDA Regarding its Pivotal C-Guardians Trial

    GlobeNewswire – 8:11 AM ET 01/18/2022

    InspireMD, Inc. (NSPR), developer of the CGuard™ Embolic Prevention Stent System for prevention of stroke caused by Carotid Artery Disease, today announced that a live case demonstration featuring CGuard™ EPS will be broadcasted at the International Symposium on Endovascular Therapy 2022 Conference by Dr. Chris Metzger, Chair of Clinical Research at Ballad Health on Tuesday, January 18, 2022.
  2. Show article details.

    BRIEF-InspireMD Reports Third Quarter 2021 Financial Results

    Reuters – 7:38 AM ET 11/09/2021

    InspireMD Inc (NSPR): * INSPIREMD REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE. * Q3 LOSS PER SHARE $0.53. * Q3 REVENUE ROSE 9.3 PERCENT TO $1.071 MILLION Source text for Eikon: Further company coverage:
  3. Show article details.

    InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update

    GlobeNewswire – 7:30 AM ET 11/09/2021

    -CGuard™ sales generated 24% YoY revenue growth- -CGuard™ EPS received a positive opinion from the French National Authority for Health regarding reimbursement in France-  - $37.1 million in cash, cash equivalents and short-term bank deposits as of September 30, 2021, provides runway into first half of 2023- -Management to host Call & Webcast Today, November 9, 2021, at 8:30am ET- TEL AVIV, Is...
  4. Show article details.

    BRIEF-InspireMD Reports Publication of 12-Month Results of CGuard EPS SIBERIA Trial

    Reuters – 6:05 PM ET 11/03/2021

    InspireMD Inc (NSPR): * INSPIREMD ANNOUNCES PUBLICATION OF 12-MONTH RESULTS OF CGUARD™ EPS SIBERIA TRIAL IN JOURNALS OF THE AMERICAN COLLEGE OF CARDIOLOGY: CARDIOVASCULAR INTERVENTIONS Source text for Eikon: Further company coverage:
  5. Show article details.

    InspireMD Announces Publication of 12-Month Results of CGuard™ EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions

    GlobeNewswire – 4:05 PM ET 11/03/2021

    InspireMD, Inc. (NSPR), developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, today announced that results from the investigator-initiated SIBERIA randomized clinical trial of CGuard EPS, that evaluated the peri-procedural and 30-day silent brain infarcts associated with the use of its MicroNet™ covered stent versus a convent...
  6. Show article details.

    InspireMD to Report Third Quarter 2021 Financial Results on November 9, 2021 and Provide Corporate Business Update

    GlobeNewswire – 8:30 AM ET 10/26/2021

    InspireMD, Inc. (NSPR), developer of the CGuard™ Embolic Prevention Stent System device for the treatment of Carotid Artery Disease and stroke prevention, today announces it will report third quarter 2021 financial results on Tuesday, November 9, 2021, before the market opens.
  7. Show article details.

    InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority for Health

    GlobeNewswire – 8:30 AM ET 10/13/2021

    InspireMD, Inc. (NSPR), a global developer of the CGuard™ Embolic Prevention Stent System device for the treatment of Carotid Artery Disease and stroke prevention, today announced that its CGuard EPS stent system has received a positive opinion from the National Commission for the Evaluation of Medical Devices and Health Technologies of the French National Authority for Health regarding reimbursement ...
  8. Show article details.

    InspireMD Announces Strong Second Quarter 2021 Financial Results

    GlobeNewswire – 7:00 AM ET 08/10/2021

    Revenue rebound, strong procedural recovery Management to host investor conference call today, August 10, 2021, at 8:30am ET InspireMD, Inc. (NSPR), developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, today announced financial and operating results as of and for the second quarter ended June 30, 2021.
  9. Show article details.

    InspireMD to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021, and Provide Corporate Update

    GlobeNewswire – 8:30 AM ET 08/04/2021

    InspireMD, Inc. (NSPR), developer of the CGuard™ Embolic Prevention Stent System device for the treatment of Carotid Artery Disease and stroke prevention, today announces it will report fiscal first quarter 2021 financial results on Tuesday, August 10, 2021, before the market opens. Following management’s formal remarks, there will be a question-and-answer session.
Page:

Today's and Upcoming Events

  • Mar
    07

    NSPR to announce Q4 earnings (Unconfirmed)

Past Events (last 90 days)

  • Nov
    09

    NSPR announced Q3 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Classic Patterns (past 90 days)

PROVIDED BY RECOGNIA, INC.

View All Technical Analysis in Advanced Chart Opens in New Window

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
Copyright 1998–2022 FMR LLC. 
All rights reserved. 
Close
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.